Home Cart Sign in  
Chemical Structure| 1228013-30-6 Chemical Structure| 1228013-30-6

Structure of Onatasertib
CAS No.: 1228013-30-6

Chemical Structure| 1228013-30-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CC-223 is a potent mTOR kinase inhibitor (IC50=16 nM), with > 150-fold sensitivity over the related lipid kinase PI3Kα (IC50=4 μM).

Synonyms: Cc-223; ATG-008

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Onatasertib

CAS No. :1228013-30-6
Formula : C21H27N5O3
M.W : 397.47
SMILES Code : O=C1CNC2=NC=C(C3=CC=C(C(C)(O)C)N=C3)N=C2N1[C@H]4CC[C@H](OC)CC4
Synonyms :
Cc-223; ATG-008
MDL No. :MFCD28976054
InChI Key :UFKLYTOEMRFKAD-UHFFFAOYSA-N
Pubchem ID :58298316

Safety of Onatasertib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Onatasertib

PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • mTOR

    mTOR, IC50:16 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
PANC-1 cells 20 μM 24 hours Inhibited proliferation, invasion, and migration of PANC-1 cells PMC7741184
Primary HCC cells (HCC1/2/3) 500 nM 72 hours CC-223 at 500 nM showed similar cytotoxicity to primary HCC cells (HCC1/2/3). PMC5363890
L02 normal hepatocytes 10-1000 nM 72 hours CC-223 at 10–1000 nM showed no significant cytotoxicity to L02 normal hepatocytes. PMC5363890
CFPAC-1 cells 20 μM 24 hours Inhibited proliferation of CFPAC-1 cells PMC7741184
BxPC-3 cells 20 μM 24 hours Inhibited proliferation of BxPC-3 cells PMC7741184
Patu8988 cells 20 μM 24 hours Inhibited proliferation of Patu8988 cells PMC7741184
SW1990 cells 20 μM 24 hours Inhibited proliferation of SW1990 cells PMC7741184
Huh-7 10-1000 nM 72 hours CC-223 at 100–1000 nM significantly reduced the survival rate of Huh-7 cells and showed a dose-dependent response. PMC5363890
KYN-2 10-1000 nM 72 hours CC-223 at 100–1000 nM significantly reduced the survival rate of KYN-2 cells and showed a dose-dependent response. PMC5363890
HepG2 10-1000 nM 72 hours CC-223 at 100–1000 nM significantly reduced the survival rate of HepG2 cells and showed a dose-dependent response. PMC5363890

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
SCID mice HepG2 xenograft model Oral 10 or 30 mg/kg body weight Once daily for 21 consecutive days Oral administration of CC-223 significantly inhibited the growth of HepG2 xenografts, showing dose-dependent activity. CC-223 also blocked mTORC1/2 activation in vivo. PMC5363890

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03591965 Hepatocellular Carcinoma PHASE2 TERMINATED 2022-08-03 Oncology Hospital of Haerbin M... More >>edical University, Harbin, Heilongjiang, 150000, China|China People PLA 81 Hospital, Nanjing, Jiangsu, 210000, China|West China Hospital Sichuan University, Chengdu, Sichuan, 610041, China|Yunnan Cancer Hospital, Kunming, Yunnan, 650118, China|The first Hospital of Jilin University, Changchun, China|Hunan Province Oncology Hospital, Changsha, China|Daping Hospital, Chongqing, China|The first hospital of Chongqing medical university, Chongqing, China|Xiehe Hospital of Fujian Medical University, Fuzhou, China|Nanfang Hospital of Nanfang Medical University, Guangzhou, China|The first affiliated Hospital of Zhejiang University, Hangzhou, China|Zhejiang Province Oncology Hospital, Hangzhou, China|The first affiliated hospital of Anhui medical university, Hefei, China|The second affiliated hospital of Anhui medical university, Hefei, China|The first affiliated hospital of Guangxi Medical University, Nanning, China|Oncology Hospital of Fudan University, Shanghai, China|Zhongshan Hospital of Fudan University, Shanghai, China|General Hospital of the Northern War Zone of the Chinese People's Liberation Army, Shenyang, China|Tangdu Hospital of China PLA fourth medical university, Xi'an, China|Dong-A University Hospital, Busan, Korea, Republic of|Pusan National Univ. Hospital, Busan, Korea, Republic of|Kyungpook National Univ. Hospital, Daegu, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Medical University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital-Linkuo, Taoyuan, Taiwan Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.52mL

0.50mL

0.25mL

12.58mL

2.52mL

1.26mL

25.16mL

5.03mL

2.52mL

References

 

Historical Records

Categories